CX1739 is a weak modulator of the AMPA-glutamate receptor (AMPAR). In mouse models, CX1739 enhances long-term potentiation in a dose-dependent manner. It also counteracts amphetamine-induced locomotor activity and rapidly reverses opioid-induced respiratory depression. CX1739 is applicable for research into dementia, neuropsychiatric disorders, and severe complications arising from opioid-induced suppression of endogenous inspiratory respiratory rhythms.